Reckitt Says Suboxone 'Product-Hopping' Didn't Harm Buyers
Reckitt Benckiser Group PLC's move to discontinue Suboxone tablets, in lieu of a new dissolving-film version of the opiate addiction treatment, presented no antitrust injury for classes of purchasers who claim...To view the full article, register now.
Already a subscriber? Click here to view full article